

AD \_\_\_\_\_

GRANT NUMBER: DAMD17-94-J-4277

TITLE: Breast Tumor Immunity in the Paraneoplastic  
Neurologic Disorders

PRINCIPAL INVESTIGATOR: Robert B. Darnell, M.D., Ph.D.

CONTRACTING ORGANIZATION: The Rockefeller University  
New York, New York 10021-6399

REPORT DATE: October 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19960124 051

DTIC QUALITY INSPECTED 1

| REPORT DOCUMENTATION PAGE   |   |   | Form Approved<br>OMB No. 0704-0188      |  |
|---|---|---|---|--|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.  |   |   |   |  |
| 1. AGENCY USE ONLY (Leave blank)  | 2. REPORT DATE<br>October 1995                              | 3. REPORT TYPE AND DATES COVERED<br>Annual 1 Oct 94 - 30 Sep 95 |   |  |
| 4. TITLE AND SUBTITLE<br>Breast Tumor Immunity in the Paraneoplastic Neurologic Disorders   |   | 5. FUNDING NUMBERS<br>DAMD17-94-J-4277                          |   |  |
| 6. AUTHOR(S)<br>Robert B. Darnell, M.D., Ph.D.  |   |   |   |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>The Rockefeller University<br>New York, New York 10021-6399   |   | 8. PERFORMING ORGANIZATION<br>REPORT NUMBER                     |   |  |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012   |   | 10. SPONSORING/MONITORING<br>AGENCY REPORT NUMBER               |   |  |
| 11. SUPPLEMENTARY NOTES   |   |   |   |  |
| 12a. DISTRIBUTION/AVAILABILITY STATEMENT<br>Approved for public release; distribution unlimited   |   | 12b. DISTRIBUTION CODE  |   |  |
| 13. ABSTRACT (Maximum 200 words) Paraneoplastic neurologic disease (PND) antigens are proteins normally expressed specifically in neurons that are expressed ectopically in tumors. It is believed that when expressed in tumors outside of the immunologically privileged nervous system, PND antigens stimulate the development of anti-tumor immunity, but also stimulate an autoimmune neuronal degeneration. We are studying PND's associated with breast cancer and immunity to the Nova and cdr2 antigens, assaying PND expression in clinical breast tumor specimens, and establishing animal models for the disorders. A prerequisite to studying the abnormal expression of PND antigens is an understanding of their normal expression. We have found that the Nova gene and antigen is normally restricted in expression to neurons. Strikingly, we have discovered that the cdr2 gene is widely expressed, but that its mRNA is under tight translational control, so that the cdr2 antigen is normally made only in neurons and (immune privileged) testes. This observation provides a novel insight to the biology of breast tumors, suggesting that they may dysregulate translational control to express abnormal proteins, and alters our approach to the analysis of cdr2 expression in vivo. We have also made significant progress in generating gene constructs to generate mouse models of PND. |   |   |   |  |
| 14. SUBJECT TERMS<br>Breast cancer, paraneoplastic neurologic disorders, tumor antigens, onconeural antigens, animal model.   |   | 15. NUMBER OF PAGES<br>13                                       |   |  |
|   |   | 16. PRICE CODE  |   |  |
| 17. SECURITY CLASSIFICATION<br>OF REPORT<br>Unclassified  | 18. SECURITY CLASSIFICATION<br>OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION<br>OF ABSTRACT<br>Unclassified      | 20. LIMITATION OF ABSTRACT<br>Unlimited |  |

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

**Block 1. Agency Use Only (Leave blank).**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

|                      |                              |
|----------------------|------------------------------|
| C - Contract         | PR - Project                 |
| G - Grant            | TA - Task                    |
| PE - Program Element | WU - Work Unit Accession No. |

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b. Distribution Code.**

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

RBD In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

RBD For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

RBD In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

RBD In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

125 B T D 10-26-95  
PI - Signature Date

TABLE OF CONTENTS:

|                              |         |
|------------------------------|---------|
| FRONT COVER .....            | p. 1    |
| SF 298 .....                 | p. 2    |
| FOREWORD .....               | p. 3    |
| TABLE OF CONTENTS .....      | p. 4    |
| INTRODUCTION .....           | p. 5    |
| BODY .....                   | p. 5-7  |
| CONCLUSIONS .....            | p. 7-8  |
| REFERENCES .....             | p. 8    |
| APPENDIX (Figures 1-6) ..... | p. 9-13 |

## INTRODUCTION:

Paraneoplastic neurologic disease (PND) antigens are proteins normally expressed specifically in the central nervous system (CNS) that are expressed ectopically in tumors; they have been termed onconeural antigens.[1] It is believed that their expression in tumors outside of the immunologically privileged CNS allows for their recognition by the immune system, and consequently a fortuitous anti-tumor immune response.[2] Tumor suppression is significant enough that the majority of PND patients present to clinicians asymptomatic from their tumors, but with newly developed neurologic symptoms. It is believed that the anti-tumor immune attack initiates the disorder, and that subsequently this immune response becomes competent to recognize neurons that normally express onconeural antigens, culminating in autoimmune neurologic disease. The most common tumors associated with PND are breast, ovarian and lung cancers.[2]

This model of the pathogenesis of PND is based largely on clinical observation. Studies of the expression and function of onconeural antigens in tumors and brain are lacking, as are animal models of their role in tumor biology and immunology. The purpose of the present work is to expand our understanding of the expression of onconeural antigens, and to develop an animal model for these syndromes. These studies are necessary to test and refine our model of the pathogenesis of these disorders. PND's provide examples of *bona fide* anti-breast tumor immunity in humans, and our hope is that the studies underway in this project will enable a detailed analysis of the mechanisms of successful anti-tumor immunity.

The methods of study in this project depend on the use of cloned genes [3-6] encoding the PND breast tumor antigens Nova and cdr2. The first specific aim is to assay clinical tumor specimens for the expression of PND genes and the presence of PND antigens. In some cases, it will also be appropriate to assay for co-factors that might be associated with the immune recognition of PND antigen (i.e. if we cannot establish a direct relationship between PND antigen expression and anti-tumor immunity). The second and third aims are complementary approaches aimed at establishing animal models for the breast tumor associated PND's, using breast tumor cell lines transfected with PND genes and transgenic mice making breast tumors expressing PND genes, respectively.

## BODY:

### Characterization of the Expression of PND Genes (Aim I):

One test of the model presented for the pathogenesis of the PND's is that the expression of onconeural antigens is normally restricted to neurons, allowing them to be recognized by the immune system as "foreign" antigens when ectopically expressed in breast tumors. A definitive analysis of the expression of the cdr2 gene has not previously been performed. We have now studied cdr2 mRNA expression by Northern blot analysis (Figure 1). Surprisingly, we find that cdr2 mRNA was abundant in all tissues, using either coding region or 3' UTR (gene specific) probes. Since this expression was particularly abundant in spleen, we confirmed expression of cdr2 mRNA in spleen by RT-PCR analysis (Figure 2), *in situ* hybridization of adult spleen with a cdr2 riboprobe (data not shown) and by sequencing a full length spleen cDNA, which was identical to the brain cdr2 cDNA (data not shown). We contrasted these results with an analysis cdr2 antigen expression by Western blot and immunohistochemical analyses, using antisera affinity purified against bacterially expressed cdr2 fusion protein (Figures 3 and 4; data not shown). These studies demonstrate that the cdr2 antigen is indeed expressed in a tissue-specific manner. The cdr2 protein and mRNA are found within discrete sets of neurons (primarily Purkinje cerebellar neurons, a few brainstem nuclei, and dorsal root ganglia; Figure 4 and data not shown), and is absent outside of the nervous system, with the exception of testes. Notably, normal breast tissue or ovarian tissue did not express cdr2 antigen. In addition, testes is notable as

the major immunologically isolated site outside of the nervous system. These studies suggest that the *cdr2* gene is under strict translational control. The mRNA is widely expressed, but the protein expression is restricted to immunologically privileged sites. Our findings are reminiscent of observations of neuron-specific gene transcription mediated by transcriptional silencers outside of the nervous system.[7] Moreover, a direct precedent for our findings can be found in studies of the expression of the BTEB transcription factor. BTEB mRNA is made in many tissues but, due to 5'-UTR translational control elements, the protein is made only in brain and testes.[8]

The observation that *cdr2* antigen expression is tissue specific is consistent with the current model of PND pathogenesis, and is particularly significant for the current project. It indicates that the study of *cdr2* mRNA in breast and ovarian tumor tissues, as originally proposed, is not the appropriate level of analysis. Rather, an analysis of *cdr2* antigen expression, as assayed by Western blot and immunohistochemistry, will be the relevant focus of study for this antigen. Consistent with these observations, our preliminary analysis of *cdr2* mRNA expression by RT-PCR analysis of non-PND breast tumor tissues revealed the presence of *cdr2* mRNA; however, interpretation of this as ectopic expression in non-PND tissues now awaits repeating this analysis with Western blot analysis. To facilitate these studies, we will use PND antisera that has been affinity purified using a *cdr2* clone, and, in addition, we have generated a polyclonal rabbit antisera specific for the *cdr2* antigen (data not shown).

Preliminary work indicated that the expression of the Nova antigen was normally restricted to neurons using PND antisera to assay protein expression.[6] However, since we have found evidence for more than one Nova gene family member (Darnell et al., unpublished data), we have pursued this observation at the level of expression of the Nova-1 gene, using a gene specific probe for *in situ* hybridization. These studies (Figure 1 and data not shown) confirm that the Nova-1 gene and antigen are restricted to neurons at all points during the normal development of mice, and support the model for the pathogenesis of the PNDs outlined in the introduction. Studies of Nova mRNA expression in non-PND breast and ovarian tumor tissue is now appropriate; mRNA has been prepared from 50 samples in a laboratory physically separated from our own (to avoid contamination that would affect RT-PCR analysis), and RT-PCR analysis of Nova mRNA expression is currently underway.

#### Animal Models of Breast Tumor Immunity #1: PND transfection of tumor cell lines (Aim 2):

These experiments will attempt to establish anti-breast tumor immunity in mice to a breast tumor cell line (RAC) transfected with the PND breast tumor antigens Nova and *cdr2*. As a prelude to setting up these cell lines, we assayed the parental RAC cells for Nova and *cdr2* expression (see below). To establish PND gene expression constructs, full length Nova and *cdr2* cDNA's have been amplified by PCR, sequenced in their entirety to ensure the integrity of the PCR reaction. A total of 3 complete *cdr2* and 3 complete Nova PCR (Pfu polymerase was used to increase fidelity of the reaction) amplified cDNA's were sequenced on both strands, yielding in each case one clone matching the native sequence. These were subcloned into mammalian expression vectors containing a selectable marker (the E. Coli *gpt* gene; Pharmacia) and transfected into RAC cells.

Figure 5 shows a Western blot analysis of Nova-1 protein expression in parental vs. Nova-transfected RAC cells. Non-transfected parental cells express no detectable Nova-1 antigen, while transfected cells express readily detectable protein levels. Similar results are found with the *cdr2* antigen (data not shown). These experiments demonstrate the fidelity of the expression vector clones, and the suitability of comparing the tumorigenicity of parental vs. transfected RAC cells in Balb/C mice as proposed.



Animal Models of Breast Tumor Immunity #2: PND expression in transgenic breast tumors (Aim 3):

In the proposed experiments, we plan to utilize currently available breast tumor transgenic mice (MMTV-wnt, neu and myc) to test the role of PND antigens in anti-tumor immunity. To adequately control these studies, we plan to adoptively transfer transgenic breast tumors that either do or do not express PND antigens into naive syngeneic mice.

The background work to establish such experiments includes an analysis of transgenic breast tumors for endogenous PND antigen expression, followed by construction of MMTV-driven PND expression vectors. To date, we have obtained MMTV-myc and MMTV-wnt breast tumor tissue (from Dr's. P. Leder and H. Varmus, respectively) for analysis of PND expression. We have analyzed these tumors for Nova antigen expression, and find no evidence that they express this antigen (Figure 6). Initial studies indicated that each tumor type expressed cdr2 mRNA (data not shown); however, given our results (above) indicating that cdr2 is under tight translational control, we are currently evaluating cdr2 antigen expression in these tumors by Western blot analysis.

Full length Nova and cdr2 cDNA constructs amplified by PCR and sequenced in shuttle vectors (above) were cloned into the MMTV-promoter mammalian expression vector pMSG (Pharmacia). The integrity of these constructs has been confirmed by transfection into RAC cells and analysis of protein expression by Western blot.

**CONCLUSIONS:**

The completed research demonstrates that the Nova and cdr2 PND antigens are both normally expressed in immune-privileged sites. This supports our general model for the pathogenesis of the breast tumor immunity seen in PND patients. That is, the immune system appears to recognize these antigens in the context of breast tumor cells as foreign antigens; their normal restriction to neurons (and testes for cdr2) sequesters them from immune surveillance and prevents their recognition as self antigens. Strikingly, we have found that the mechanisms for sequestering Nova and cdr2 antigens to neurons are very different. Nova mRNA and protein are found to be sequestered to neurons at all developmental times. In contrast, cdr2 mRNA is widely expressed in various tissues; within the nervous system its expression is fairly restricted to Purkinje cerebellar neurons, brainstem neurons and dorsal root ganglia, but outside the nervous system many tissues express the gene. Tight restriction of cdr2 antigen expression to neurons and testes is demonstrated by Western blot and immunohistochemical analysis, leading to the conclusion that translational regulatory mechanisms restrict the expression of cdr2 to immune-privileged sites.

These observations have important implications for breast tumor biology, suggesting for example that tumors that ectopically express cdr2 antigen have dysregulated translational control mechanisms. Such dysregulation has not been previously observed in breast tumors, and suggests a possible target for therapeutic intervention. Moreover, these observations recommend changes in our future work to better address the issue of the induction of ectopic PND antigen expression in tumors. Specifically, we are interested in analyzing normal and PND breast tumors for the expression of Nova and cdr2. We originally envisioned focusing on the analysis of mRNA expression using RT-PCR in such experiments. Given our current understanding of cdr2 regulation, however, we will now switch our plan to include a careful analysis of both mRNA and protein expression (analyzed by Western blot analysis) in these tumors.

Finally, we have made significant progress in generating and testing gene constructs for the construction of animal models of PND, and have performed important controls assaying Nova and cdr2 protein expression in tumors obtained from transgenic breast tumor mice and breast tumor cell lines. One recommended change in our constructs derived from our



work on cdr2 is that all expression constructs will include coding sequence without any 5'-UTR sequence. In order to obtain efficient ectopic expression of cdr2 protein in our animal models, we need to circumvent potential down regulatory translational control elements in the cdr2 mRNA, and, based on the literature [8], we predict that they reside in the 5'-UTR.

## REFERENCES:

1. Darnell, R.B., H.M. Furneaux, and J.R. Posner, *Antiserum from a patient with cerebellar degeneration identifies a novel protein in Purkinje cells, cortical neurons, and neuroectodermal tumors*. J Neuroscience, 1991. **11**: p. 1224-1230.
2. Posner, J.B. and H.M. Furneaux, *Paraneoplastic syndromes*, in *Immunologic mechanisms in neurologic and psychiatric disease*, B.H. Waksman, Editor. 1990, Raven Press, Ltd.: New York. p. 187-219.
3. Corradi, J. and R. Darnell, *The paraneoplastic antigen CDR2, a Purkinje neuron-specific leucine zipper protein, has a novel structure in tumor cells*. J Cell Biochem, 1993. **17**: p. 251.
4. Sakai, K., et al., *Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal antibody from a patient with paraneoplastic cerebellar degeneration*. Ann Neurol, 1990. **28**: p. 692-698.
5. Fathallah-Shaykh, H., et al., *Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration*. Proc Natl Acad Sci USA, 1991. **88**: p. 3451-3454.
6. Buckanovich, R., J.B. Posner, and R.B. Darnell, *Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system*. Neuron, 1993. **11**: p. 657-672.
7. Chong, J.A., et al., *REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons*. Cell, 1995. **80**: p. 949-957.
8. Imataka, H., et al., *Cell-specific translational control of transcription factor BTEB expression*. J Biol Chem, 1994. **269**: p. 20668-20673.

**Figure 1**




Figure 1. Analysis of cdr2 mRNA. Total RNA was extracted from the indicated mouse tissues, run on denaturing formaldehyde gels, transferred to nitrocellulose and probed with the indicated gene-specific probes. cdr2 mRNA of approximately 2.4kb could be detected in all tissues, with particularly robust expression in spleen, testes, brain, kidney, heart and ovary. RNA from starved samples (liver, lung, small intestine) was visibly degraded by EtBr staining; independent blots confirmed cdr2 expression in lung and small intestine.

**Figure 2**




Figure 2. RT-PCR analysis of *cdr2* mRNA in neuronal and non-neuronal tissues. Total or poly A+ RNA was prepared from the indicated tissues. Duplicate samples underwent reverse transcription and PCR with the *cdr2* primers or actin control primers, in the absence or presence of reverse transcriptase (to control for contaminating DNA). *cdr2* mRNA yielded RT-dependent PCR products of the expected size with *cdr2* primers from heart, cerebellum and spleen mRNA.

**Figure 3**




Figure 3. Western blot analysis of cdr2 antigen expression in mouse tissues. A. Extracts of normal mouse tissues were run on SDS-PAGE and probed with cdr2 (Yo) paraneoplastic disease antiserum. cdr2 antigen of the expected size (~52kD; arrow) was detected in cerebellum and spleen, with a fainter signal evident in cortex; there is no detectable antigen in non-neuronal tissues with the exception of testes. B. The same blot was stripped and reprobed with an antibody to tubulin, demonstrating the presence of approximately equal amounts of protein in each lane.

**Figure 4**




Figure 4. Neuron-specific expression of cdr2 protein and mRNA. A. An 8 $\mu$ M frozen section of mouse cerebellum was probed with cdr2 (Yo) PND antiserum and visualized by avidin-biotin peroxidase immunohistochemistry. Expression of the cdr2 antigen is restricted to Purkinje neurons in the cerebellum. B. An 8 $\mu$ M frozen section of mouse cerebellum was probed with a  $^{33}\text{P}$ -labeled cdr2 antisense riboprobe and visualized by dark field microscopy. The cdr2 mRNA is restricted to Purkinje neurons in the cerebellum.

**Figure 5**

**RAC cell transfections**




Figure 5. Western blot analysis of RAC breast tumor cell lines stably transfected (Eco gpt selection) with a Nova-1 expression vector (+ Nova) or a parental plasmid vector (-control). Extracts of RAC cells were run on Western blots and probed with Nova paraneoplastic disease antiserum. Nova antigen is readily detected in Nova-1 transfected cells but not in mock transfected cells.

**Figure 6**




Figure 6. Western blot analysis of Nova antigen expression in transgenic breast tumor tissues. A. Extracts of breast tumors dissected from MMTV-wnt or MMTV-myc transgenic mice were run on Western blots and probed with Nova paraneoplastic disease antiserum. Nova antigen is readily detected in brain extracts, but is not evident in normal mouse mammary or spleen, nor in transgenic breast tumor tissues. B. Coomassie blue stain of samples probed in (A), demonstrating that an approximately equal amount of protein was loaded in each lane.